Neuropsychiatric Signs and Symptoms of Alzheimer's Disease: New Treatment Paradigms

The Roles of Inflammation and Immune Mechanisms in Alzheimer's Disease

Additional/Co-morbid Neuropathologies in the setting of Alzheimer's Disease
Neuropathology: Impact on Drug Development

Tau: From research to clinical development
David M. Holtzman, Maria C. Carrillo, James A. Hendrix, Lisa J. Bain, Ana M. Catafau, Laura M. Gault, Eckhard Mandelkow, Eva-Maria Mandelkow, David S. Miller, Susanne Ostrowitzki, Manuela Polydoro, Sean Smith, Marion Wittmann, Michael Hutton Alzheimer's & Dementia Published online: May 3 2016

Challenges, Solutions and Consensus Recommendations for Alzheimer's Disease Combination Therapy

Considerations for the assessment of suicidal ideation and behavior in older adults with cognitive decline and dementia
Cited in Scopus: 1

Suicidal ideation and behavior assessment in dementia studies: An Internet survey
Cited in Scopus: 1
Revolution of Alzheimer’s Disease Understanding and Trials Through Biomarkers
Spring, 2014

Assessing Cognition and Function in Alzheimer’s Disease Clinical Trials: Do We Have the Right Tools?
Cited in Scopus: 0
Published in issue: November, 2014

Justifying Reimbursement for Alzheimer’s Diagnostics and Treatments: Seeking Alignment on Evidence
Norman L. Foster, Judith S.M. Hackett, Greg White, Sherri Chenevert, Patrick Svarvar, Lisa Bain, Maria C. Carrillo

Revisiting the Framework of the National Institute on Aging-Alzheimer’s Association Diagnostic Criteria, October 2012

Let’s Get Real About Non-Amyloid Targets in Alzheimer’s Disease, April 2012

Prevention Trials in Alzheimer’s Disease, October 2011

Phase II Clinical Trials in Alzheimer’s Disease, June 2011

Epidemiology of Alzheimer’s Disease, October 2010
VE Expert Working Group Meeting, October 2010
Sperling, RA, Jack, CR., Black, SE, Frosch, MP, Greenberg, SM, Hyman, BT, Scheltens, P, Carrillo, MC, Thies, W, Bednar, MM, Black, RS, Brashear, HR, Grundman, M, Siemers, ER. Feldman, HH, Schindler, RS. Amyloid Related Imaging Abnormalities (ARIA) in Amyloid


Challenges in NPS in Alzheimer’s Disease, April 2010

Global Clinical Trials in Alzheimer’s Drug Development Meeting, November 2009

Alzheimer’s Disease Classification Meeting, April 2009

Optimal Trial Design for Alzheimer’s Drug Discovery Meeting, November 2008
Not published

Scales for Alzheimer’s Disease Meeting, April 2008

Early Risk Assessment for Alzheimer’s Disease Meeting, November 2007

Academic/Industry Interface for Alzheimer’s Drug Discovery Meeting, April 2007

Health Economics & Real World Value of AD Therapy Meeting, November 2006:


**Cytoskeletal Meeting, April 2006:**


**Optimal Trial Design Meeting, November 2005:**


Finding potent drugs for Alzheimer’s disease is more important than proving the drugs are disease modifying. Knopman, D. *Alzheimer’s & Dementia* (2006).


**Biomarkers Meeting, April 2005:**


**MCI Meeting, September 2004:**